TYK2 Inhibitor Scaffolds for JAK2-Sparing Autoimmune Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions mediated by TYK2, such as inflammatory bowel disease, autoimmune disorders, and cancer, lack selective inhibitors that minimize off-target effects on other JAK kinases like JAK2, leading to unwanted side effects.
Innovation Solution
Development of compounds that selectively inhibit TYK2 activity, reducing the impact on other JAK kinases, particularly JAK2, to treat conditions like inflammatory bowel disease, autoimmune disorders, and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective JAK inhibitors are used to treat TYK2-mediated conditions, then broad inhibition of JAK family kinases is achieved, but off-target effects on JAK2 and other kinases occur causing unwanted side effects
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular characteristics that confer selective binding to TYK2 versus other JAK family members. The compounds contain structural features (such as specific heterocyclic rings, substituent patterns, and spatial arrangements) that match the unique binding pocket geometry of TYK2, allowing selective inhibition of this target while sparing JAK1, JAK2, and JAK3. This structural specificity enables the drug to act locally on the intended target without affecting other similar kinases.
Solution Approach 2:
The patent employs parameter changes by systematically modifying chemical parameters of the inhibitor molecules to optimize TYK2 selectivity. This includes adjusting molecular weight, hydrophobicity, hydrogen bonding capacity, and steric properties of different substituents. By fine-tuning these chemical parameters, the inhibitors achieve optimal binding affinity for TYK2 while maintaining reduced affinity for other JAK family members, thereby resolving the selectivity issue.
2Object-affected harmful factors
If selective TYK2 inhibitors are developed to minimize off-target effects, then side effects are reduced, but the complexity of drug design and development increases
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional segments or pharmacophores, each contributing to specific binding interactions with TYK2. This modular approach allows medicinal chemists to independently optimize each segment for selectivity and affinity, simplifying the overall design process. The segmented structure also facilitates structure-activity relationship (SAR) studies by allowing systematic modification of individual segments to enhance TYK2 selectivity.
Solution Approach 2:
The patent uses intermediary structures as mediators in the drug design process. These intermediary compounds serve as scaffolds or linkers that connect different functional groups and facilitate the achievement of selective TYK2 binding. The intermediaries act as building blocks that can be systematically modified to optimize selectivity, reducing the overall complexity of designing fully selective inhibitors from scratch.
Data Source
AI summary
Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.